ATE389405T1 - Fexofenadine hydrochlorid polymorph - Google Patents

Fexofenadine hydrochlorid polymorph

Info

Publication number
ATE389405T1
ATE389405T1 AT02751479T AT02751479T ATE389405T1 AT E389405 T1 ATE389405 T1 AT E389405T1 AT 02751479 T AT02751479 T AT 02751479T AT 02751479 T AT02751479 T AT 02751479T AT E389405 T1 ATE389405 T1 AT E389405T1
Authority
AT
Austria
Prior art keywords
polymorpho
fexofenadine hydrochloride
polymorph
fexofenadine
hydrochloride
Prior art date
Application number
AT02751479T
Other languages
English (en)
Inventor
Frederico Junquera Milla
Original Assignee
Texcontor Ets
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texcontor Ets filed Critical Texcontor Ets
Application granted granted Critical
Publication of ATE389405T1 publication Critical patent/ATE389405T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02751479T 2001-07-31 2002-07-29 Fexofenadine hydrochlorid polymorph ATE389405T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01610081 2001-07-31

Publications (1)

Publication Number Publication Date
ATE389405T1 true ATE389405T1 (de) 2008-04-15

Family

ID=8183555

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02751479T ATE389405T1 (de) 2001-07-31 2002-07-29 Fexofenadine hydrochlorid polymorph

Country Status (7)

Country Link
US (2) US20040248935A1 (de)
EP (1) EP1414453B1 (de)
AT (1) ATE389405T1 (de)
DE (1) DE60225694T2 (de)
ES (1) ES2301662T3 (de)
PT (1) PT1414453E (de)
WO (1) WO2003011295A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK13822003A3 (sk) * 2001-04-09 2004-09-08 Teva Pharmaceutical Industries Ltd. Polymorfné formy chloridu fexofenadínu
JP2005532356A (ja) 2002-06-10 2005-10-27 テバ ファーマシューティカル インダストリーズ リミティド 塩酸フェキソフェナジンの多型体ｘｖｉ
GB0319935D0 (en) * 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
WO2005102999A2 (en) * 2004-04-26 2005-11-03 Teva Pharmaceutical Industries Ltd. Crystalline forms of fexofenadine hydrochloride and processes for their preparation
ITMI20041143A1 (it) * 2004-06-08 2004-09-08 Dipharma Spa Polimorfi di fexofenadina e procedimento per la loro preparazione
WO2007052310A2 (en) * 2005-11-03 2007-05-10 Morepen Laboratories Limited Polymorphs of fexofenadine hydrochloride and process for their preparation
DOP2006000274A (es) 2005-12-14 2007-10-15 Sanofi Aventis Us Llc Formulación de suspensión de fexofenadina
AU2007272951A1 (en) * 2006-07-11 2008-01-17 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
EP2105134A1 (de) 2008-03-24 2009-09-30 Ranbaxy Laboratories Limited Stabiles und amorphes Fexofenadin-Hydrochlorid
WO2010083360A2 (en) * 2009-01-16 2010-07-22 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
WO2011158262A1 (en) 2010-06-15 2011-12-22 Chemelectiva S.R.L. Polymorphic form of fexofenadine hydrochloride, intermediates and process for its preparation
CN104072402B (zh) * 2014-07-16 2016-08-17 昆山龙灯瑞迪制药有限公司 一种新结晶形式的盐酸非索非那定化合物及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT766668E (pt) * 1994-05-18 2002-11-29 Aventis Pharma Inc Processos para a preparacao de formas anidras e hidratadas de derivados antihistaminicos da piperidina e de polimorfos e pseudomorfos destes
KR100405116B1 (ko) * 1995-02-28 2004-02-05 아벤티스 파마슈티칼스 인크. 피페리디노알칸올화합물에대한약제학적조성물

Also Published As

Publication number Publication date
EP1414453B1 (de) 2008-03-19
PT1414453E (pt) 2008-05-29
WO2003011295B1 (en) 2003-04-03
EP1414453A1 (de) 2004-05-06
US20100010229A1 (en) 2010-01-14
ES2301662T3 (es) 2008-07-01
WO2003011295A1 (en) 2003-02-13
DE60225694T2 (de) 2008-06-26
US20040248935A1 (en) 2004-12-09
DE60225694D1 (de) 2008-04-30

Similar Documents

Publication Publication Date Title
LU92880I2 (fr) Evérolimus ou un sel pharmaceutiquement acceptablequi en dérive (afinitor)
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
GB0124627D0 (en) Novel compounds
DK1506185T3 (da) Forbindelser og deres anvendelse som 5-HT-inhibitorer
DE60210944D1 (de) N-substituierte heterocyclische nichtaryl-nmda/nr2b-antagonisten
MXPA05009367A (es) Antagonistas del receptor opioide.
NO20062644L (no) DPP-IV inhibitorer
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
NO20042811L (no) Substituerte henzoksazoler og analoger som estrogene midler
ATE478049T1 (de) Phosphodiesterase-4-inhibitoren, einschliesslich n-substituierter diarylaminanaloga
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
NO20052739D0 (no) CCR5-antagonister som medikamenter
MXPA03011039A (es) Nuevos compuestos heterociclicos, su preparacion y uso como medicamentos, particularmente como agentes anti-bacterianos.
NO20054787D0 (no) Indenderivater som farmasotiske midler
ATE308522T1 (de) Opioidrezeptorantagonisten
HRP20090159T1 (en) Use of glucosidase inhibitors for therapy of mucovisidosis
EA200801199A1 (ru) Ингибиторы киназы
DK1814848T3 (da) 2,3,4-substitueret-cyclopentanoner som terapeutiske midler
IL172542A0 (en) 2-hydroxymethyl-3,4,5-trihydroxy-1-benzilpiperidine derivatives as inhibitors of glucosylceramide
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
ATE389405T1 (de) Fexofenadine hydrochlorid polymorph
NO20042916L (no) HIV integrase inhibitorer
WO2009106599A3 (en) Substituted piperidines as therapeutic compounds
WO2003037916A3 (en) Linear basic compounds having nk-2 antagonist activity and formulations thereof
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1414453

Country of ref document: EP

REN Ceased due to non-payment of the annual fee